WO2024214019 - TETRACYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
National phase entry is expected:
Publication Number
WO/2024/214019
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053500
International Filing Date
10.04.2024
Title **
[English]
TETRACYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
[French]
COMPOSÉS TÉTRACYCLIQUES UTILISÉS EN TANT QUE AGENTS DE DÉGRADATION DE SMARCA2 ET/OU DE SMARCA4
Applicants **
AURIGENE ONCOLOGY LIMITED
39/40 (P), KIADB Industrial Area, Electronics City Phase II
Bangalore 560100, IN
Inventors
ABBINENI, Chandrasekhar
15-21-48/14/G-3, SriSai DattaEnclave, Balaji Nagar, Kukatpally
Hyderabad 500072, IN
SAMAJDAR, Susanta
R 801, HMTambourine, JP Nagar 6th Phase
Bangalore 560078, IN
KUILA, Bilash
Vill+PO+PS-Shyampur, Howrah, West Bengal
Howrah 711314, IN
Priority Data
202341027216
12.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2502 | |
| EPO | Filing, Examination | 15043 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 13085 |
Total: 31735 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides tetracyclic compound of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.[French]
La présente invention concerne des composés tétracycliques de formule (I), qui sont thérapeutiquement utiles en tant qu'agents de dégradation de SMARCA2 et/ou de SMARCA4. Ces composés sont utiles dans le traitement et/ou la prévention de maladies ou de troubles dépendant de SMARCA2 et/ou SMARCA4 chez un sujet. La présente invention concerne également la préparation des composés et des compositions pharmaceutiques comprenant un composé de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère ou un tautomère de celui-ci.